[Drug interactions: new mechanisms and clinical relevance].
Paneitz
A
A
Institut für Pharmakologie, Ernst-Moritz-Arndt-Universität, Greifswald.
Meissner
K
K
Kroemer
H K
HK
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000009:adverse effects; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004347:Drug Interactions / Q000502:physiology*; D018432:Drug Resistance, Multiple / Q000235:genetics / Q000502:physiology; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D020748:Mibefradil / Q000009:adverse effects; D010599:Pharmacokinetics; D011110:Polymorphism, Genetic
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018528:ATP-Binding Cassette Transporters; D002121:Calcium Channel Blockers; D002352:Carrier Proteins; D020748:Mibefradil; D003577:Cytochrome P-450 Enzyme System